Halozyme Therapeutics (HALO) earnings per share (EPS)

Earnings per share · fiscal 2025
$2.56

Halozyme Therapeutics (HALO) reported diluted earnings per share of $2.56 in fiscal 2025 (the year ended December 31, 2025). That is 25.4% lower than the $3.43 of fiscal 2024. Figures as of 17 Nov 2026, 23:42 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings per share, fiscal 2025
$2.56
Change on fiscal 2024
−25.4%
Growth, 5 years
+23.0% a year
Highest on record
$3.43fiscal 2024
Lowest on record
-$0.81fiscal 2016
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Halozyme Therapeutics earnings per share (EPS), in more detail

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 23.0% a year. Across the 11 fiscal years on record (2015–2025), the highest was $3.43 in fiscal 2024 and the lowest -$0.81 in fiscal 2016.

History · 11 fiscal years

Earnings per share by fiscal year

Halozyme Therapeutics earnings per share (EPS), year by year

Halozyme Therapeutics (HALO) earnings per share (EPS) by fiscal year
Fiscal yearEarnings per shareChangeYear ended
2025$2.56 25.4% down
2024$3.43 63.3% up
2023$2.10 45.8% up
2022$1.44 47.4% down
2021$2.74 201.1% up
2020$0.91—
2019-$0.50—
2018-$0.56 224.4% down
2017$0.45—
2016-$0.81—
2015-$0.25—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

Earnings per share at health care companies of similar size

Earnings per share of Halozyme Therapeutics and comparable companies
CompanyEarnings per shareFiscal year
Fresenius Medical Care FMS€1.682025
Kymera Therapeutics KYMR-$3.692025
DaVita DVA$9.842025
Halozyme Therapeutics HALO$2.562025
Universal Health Services UHS$23.102025
Repligen RGEN$0.862025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics earnings per share (EPS): questions and answers

What is Halozyme Therapeutics's diluted earnings per share?

Halozyme Therapeutics (HALO) reported diluted earnings per share of $2.56 in fiscal 2025 (the year ended December 31, 2025). That is 25.4% lower than the $3.43 of fiscal 2024.

What is the growth rate of Halozyme Therapeutics's diluted earnings per share?

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 23.0% a year.

What are the highest and lowest diluted earnings per share figures on record for Halozyme Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $3.43 in fiscal 2024 and the lowest -$0.81 in fiscal 2016.

How is Halozyme Therapeutics's diluted earnings per share calculated?

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/HALO/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.